Table 1.
Comparative composition of CB-PRP derivatives.
| Paired | Unpaired | |||||||
|---|---|---|---|---|---|---|---|---|
| Analyte | Sample | Concentration mean ± SEM | p-Value CB-PPP vs. CB-PL | p-Value CB-PPP vs. CB-PR | p-Value CB-PR vs. CB-PL | p-Value CB-PPP vs. CB-PL | p-Value CB-PPP vs. CB-PR | p-Value CB-PR vs. CB-PL |
| Group I (trophic and wound healing factors) | ||||||||
| pg/mL | ||||||||
| EGF | CB-PPP | 93.5 ± 5 | 0.0004 | 0.0110 | >0.9999 | 0.0002 | 0.008 | >0.9999 |
| CB-PL | 858 ± 66 | |||||||
| CB-PR | 800.6 ± 54 | |||||||
| bFGF | CB-PPP | 179.5 ± 5 | 0.0004 | 0.0110 | 0.9999 | 0.0001 | 0.0011 | >0.9999 |
| CB-PL | 348 ± 26 | |||||||
| CB-PR | 310 ± 21 | |||||||
| HGF | CB-PPP | 1446 ± 204 | 0.0553 | 0.29669 | 0.0002 | >0.9999 | 0.6702 | 0.1399 |
| CB-PL | 1676 ± 227 | |||||||
| CB-PR | 1127 ± 116 | |||||||
| TGF-β1 | CB-PPP | 8767 ± 929 | 0.0002 | 0.1365 | 0.1365 | 0.0003 | 0.0126 | 0.8665 |
| CB-PL | 58646 ± 3553 | |||||||
| CB-PR | 49461 ± 3949 | |||||||
| Group II (pro-angiogenic factors) | ||||||||
| pg/mL | ||||||||
| VEGF | CB-PPP | 329 ± 17 | <0.0001 | 0.0760 | 0.0760 | <0.0001 | 0.0038 | 0.7279 |
| CB-PL | 1046 ± 367 | |||||||
| CB-PR | 798 ± 90 | |||||||
| PDGF AB/BB | CB-PPP | 3388 ± 535.5 | <0.0001 | 0.1017 | 0.1017 | <0.0001 | 0.0569 | 0.0447 |
| CB-PL | 37267 ± 1817 | |||||||
| CB-PR | 10276 ± 752 | |||||||
| ng/mL | ||||||||
| MMP-2 | CB-PPP | 170 ± 8 | >0.9999 | 0.0012 | 0.0140 | >0.9999 | 0.0905 | 0.1607 |
| CB-PL | 153 ± 9 | |||||||
| CB-PR | 140 ± 7.7 | |||||||
| MMP-9 | CB-PPP | 101 ± 12 | 0.0286 | 0.0005 | 0.7158 | >0.9999 | 0.8959 | >0.9999 |
| CB-PL | 88 ± 12 | |||||||
| CB-PR | 83.4 ± 13 | |||||||
| TIMP-1 | CB-PPP | 157 ± 12 | 0.0733 | 0.0005 | 0.4008 | 0.0100 | 0.0003 | >0.9999 |
| CB-PL | 332 ± 18 | |||||||
| CB-PR | 372 ± 11 | |||||||
| TIMP-2 | CB-PPP | 48 ± 2.6 | 0.2969 | 0.0553 | 0.0002 | 0.8156 | 0.0720 | 0.0024 |
| CB-PL | 48.7 ± 2 | |||||||
| CB-PR | 38.8 ± 2.5 | |||||||
| TIMP-3 | CB-PPP | 1.1 ± 0.01 | 0.0029 | 0.0065 | >0.9999 | 0.0019 | 0.0033 | >0.9999 |
| CB-PL | 2.8 ± 0.2 | |||||||
| CB-PR | 3.0 ± 0.3 | |||||||
| TIMP-4 | CB-PPP | 1.8 ± 0.2 | 0.2969 | 0.0553 | 0.0002 | 0.8156 | 0.7047 | 0.0667 |
| CB-PL | 2.0 ± 0.2 | |||||||
| CB-PR | 1.5 ± 0.2 | |||||||
| Group III.A (pro-inflammatory GFs and cytokines) | ||||||||
| pg/mL | ||||||||
| IL-6 | CB-PPP | 77 ± 10 | 0.0140 | >0.9999 | 0.1017 | 0.0778 | >0.9999 | 0.4621 |
| CB-PL | 98 ± 6 | |||||||
| CB-PR | 82 ± 5 | |||||||
| IL-1α | CB-PPP | 40.5 ± 1.0 | <0.0001 | 0.1017 | 0.1017 | <0.0001 | 0.0081 | 0.6702 |
| CB-PL | 88 ± 8 | |||||||
| CB-PR | 69 ± 4 | |||||||
| TNF-α | CB-PPP | 103 ± 1.6 | 0.0024 | 0.0024 | >0.9999 | 0.0008 | 0.0009 | >0.9999 |
| CB-PL | 123.6 ± 4 | |||||||
| CB-PR | 122 ± 2 | |||||||
| Group III.B (anti-inflammatory cytokines) | ||||||||
| pg/mL | ||||||||
| IL-10 | CB-PPP | 43.5 ± 0.8 | 0.0004 | 0.0110 | >0.9999 | <0.0001 | 0.0020 | >0.9999 |
| CB-PL | 72 ± 8 | |||||||
| CB-PR | 63.8 ± 3 | |||||||
Non-parametric comparison test. n = 10/product type.